IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
19 April 2023 - 9:00PM
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage
biotechnology company focused on creating and developing engineered
IgM antibodies, today announced that Fred Schwarzer, Chief
Executive Officer, will participate in a virtual fireside chat at
the Stifel 2023 Targeted Oncology Days on Wednesday, April 26,
2023, at 3:00 p.m. EDT.
A live webcast of the event will be available on the “Events and
Presentations” page in the “Investors” section of the Company’s
website at
https://investor.igmbio.com/news-and-events/events-and-presentations.
A replay of the webcast will be archived on the Company’s website
for 90 days following the presentation.
About IGM Biosciences, Inc.IGM Biosciences is a
clinical-stage biotechnology company committed to developing and
delivering a new class of medicines to treat patients with cancer,
autoimmune and inflammatory diseases and infectious diseases. The
Company’s pipeline of clinical and preclinical assets is based on
the IgM antibody, which has 10 binding sites compared to
conventional IgG antibodies with only 2 binding sites. The Company
also has an exclusive worldwide collaboration agreement with Sanofi
to create, develop, manufacture, and commercialize IgM antibody
agonists against oncology and immunology and inflammation targets.
For more information, please visit www.igmbio.com.
ContactArgot PartnersDavid
Pitts212-600-1902igmbio@argotpartners.com
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Jul 2024 to Aug 2024
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Aug 2023 to Aug 2024